Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library

Kobayashi, Sohei; Hiwasa, Takaki; Arasawa, Takahiro; Kagaya, Akiko; Ishii, Shuji; Shimada, Hideaki; Ito, Masaaki; Suzuki, Motoo; Kano, Masayuki; Rahmutulla, Bahityar; Kïtamura, Kazuo; Sawabe, Yuji; Shin, Hideo; Takao, Masaki; Nomura, Fumio; Matsubara, Hisahiro; Matsushita, Hiroshi

doi:10.18632/oncotarget.24963

Cited by 29 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, FIRΔexon2 Abs with anti‐p53 Abs or CEA improves the specificity and sensitivity for screening ESCCs. Further prospective multi‐institutional studies comparing the sensitivity and specificity of this combinational detection approach will be required …”

Section: Discussionmentioning

confidence: 99%

“…Prior to development, highly malignant tumors can induce necrosis, leading to the exposure of intracellular antigenic proteins to plasma. Therefore, using combinational Ab detection approaches could allow for the precise early detection of tumors . In this study, we explored and examined 5 SEREX antigen markers for improved efficiency in diagnosing ESCC.…”

Section: Discussionmentioning

confidence: 99%

“…Further prospective multi-institutional studies comparing the sensitivity and specificity of this combinational detection approach will be required. 28 Amplified luminescence proximity homogeneous assay is an excellent method for measuring Ab levels compared with ELISA because of its low variation, stable background, and high specificity. It does not involve plate-washing steps; however, it involves mixing antigens with Abs in sera followed by the addition of donor and acceptor beads.…”

Section: Discussionmentioning

confidence: 99%

“…Anti‐PUF60 autoantibodies are reportedly detected in the sera of patients with autoimmune diseases such as dermatomyositis, Sjögren's syndrome, and idiopathic inflammatory myopathy . This suggests that the combination of anti‐FIR Abs with other clinically available tumor markers, such as anti‐p53 Abs, CEA, and CA19‐9, could increase the specificity and accuracy of diagnosis . The present study aimed to explore the presence and significance of anti‐FIRΔexon2 Abs in the sera of patients with ESCC and to determine its use as a potential candidate marker.…”

Section: Introductionmentioning

confidence: 97%

“…26,27 This suggests that the combination of anti-FIR Abs with other clinically available tumor markers, such as anti-p53 Abs, CEA, and CA19-9, could increase the specificity and accuracy of diagnosis. [28][29][30][31][32] The present study aimed to explore the presence and significance of anti-FIRΔexon2 Abs in the sera of patients with ESCC and to determine its use as a potential candidate marker.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Anti‐FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Anti‐ PUF 60 autoantibodies are reportedly detected in the sera of patients with dermatomyositis and Sjögren's syndrome; however, little is known regarding its existence in the sera of cancer patients. FIR , a splicing variant of the PUF 60 gene, is a transcriptional repressor of c‐myc . In colorectal cancer, there is an overexpression of the dominant negative form of FIR , in which exon 2 is lacking ( FIR Δexon2). Previously, large‐scale SEREX (serological identification of antigens by recombinant cDNA expression cloning) screenings have identified anti‐ FIR autoantibodies in the sera of cancer patients. In the present study, we revealed the presence and significance of anti‐ FIR ( FIR / FIR Δexon2) Abs in the sera of patients with esophageal squamous cell carcinoma ( ESCC ). Our results were validated by an amplified luminescence proximity homogeneous assay using sera of patients with various cancer types. We revealed that anti‐ FIR Δexon2 Ab had higher sensitivity than anti‐ FIR Ab. Receiver operating characteristic (ROC) analysis was applied for evaluating the use of anti‐ FIR Δexon2 Ab as candidate markers such as anti‐p53 Ab and carcinoembryonic antigen, and the highest area under the ROC curve was observed in the combination of anti‐ FIR Δexon2 Ab and anti‐p53 Ab. In summary, our results suggest the use of anti‐ FIR Δexon2 Ab in combination with the anti‐p53 Ab as a predictive marker for ESCC . The area under the ROC curve was further increased in the advanced stage of ESCC . The value of anti‐ FIR Δexon2 autoantibody as novel clinical indicator against ESCC and as a companion diagnostic tool is discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Anti‐FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Combinational antibody detection approach increases the clinical validity of colorectal cancer screening

Kobayashi,

Hiwasa,

Kitamura

et al. 2023

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

BackgroundAt different stages of the disease, biomarkers can help to determine disease progression and recurrence and provide a personalized indicator of therapeutic effectiveness. The serological identification of antigens by recombinant cDNA expression cloning (SEREX) has identified five SEREX antigens.ResultsCompared with healthy donors, anti‐FIRΔexon2 and anti‐SOHLH antibodies (Abs) in the sera of patients with colorectal cancer (CRC) were markedly higher. Furthermore, no correlation was noted between five SEREX antigens and the three tumor markers (CEA, CA19‐9, and anti‐p53 Abs), indicating that anti‐FIRΔexon2 Abs are an independent candidate marker for patients with CRC. Generally, the levels of anti‐FIRΔexon2 Abs combined with clinically available tumor markers were determined to be significantly higher compared with CEA, CA19‐9. Moreover, in early‐stage CRC, the levels of anti‐FIRΔexon2 Abs combined with existing tumor markers were higher than those of CEA, CA19‐9.ConclusionDue to the highly heterogeneous nature of CRC, a single tumor marker is unlikely to become a standalone diagnostic test due to its commonly insufficient sensitivity and/or specificity. Using a combination antibody detection approach of tumor markers for CRC diagnosis has the potential to be an effective approach. Therefore, the use of serum protein biomarker candidates holds promise for the development of inexpensive, noninvasive, and inexpensive tests for the detection of CRC.

show abstract

Immunoproteomics Methods and Techniques

Fulton

Baltat

Twine

2019

Methods in Molecular Biology

View full text Add to dashboard Cite

Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library

Cited by 29 publications

References 24 publications

Anti‐FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma

Anti‐FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma

Combinational antibody detection approach increases the clinical validity of colorectal cancer screening

Immunoproteomics Methods and Techniques

Contact Info

Product

Resources

About